TGA approves new eye treatment

A second treatment for geographic atrophy has been approved by the TGA, although there is still no subsidised treatment for the condition.

Astellas' Izervay has been listed on the ARTG, indicated for the treatment of adult patients with Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) with an intact fovea and when central vision is threatened by GA lesion growth, after 17 months before the PBAC.

It's the same indication as Apellis' Syfovre, which was approved by the TGA in January after a two-year review, as the first treatment for GA approved in Australia. That's on the PBAC agenda for November.